FDA Advancing Generic Drug Development 2025: Recommendations for Topical and Mucosal Products

Download video

FDA Advancing Generic Drug Development 2025: Recommendations for Topical and Mucosal Products

14 views

The FDA Learning Cache

11 days ago

FDA Advancing Generic Drug Development 2025: Recommendations for Topical and Mucosal Products

17:36

FDA Advancing Generic Drug Development 2025: Recommendations for Topical and Mucosal Products

by The FDA Learning Cache

23:46

FDA Advancing Generic Drugs 2025: Population Selection and Mitigation Strategies in BE Studies

by The FDA Learning Cache

27:41

FDA Advancing Generic Drugs 2025: Biopharmaceutics Classification System Waiver Option in PSGs

by The FDA Learning Cache

$FDA Advancing Generic Drug Development 2025: Session 2: Q\&A Panel and Day 1 Closing$

37:41

FDA Advancing Generic Drug Development 2025: Session 2: Q\&A Panel and Day 1 Closing

by The FDA Learning Cache

20:23

FDA Advancing Generic Drug Development 2025: SME Triage Team: Product-Specific Guidance Development

by The FDA Learning Cache

$FDA Advancing Generic Drug Development 2025: Session 4: Q\&A Panel and Day Two Closing$

39:13

FDA Advancing Generic Drug Development 2025: Session 4: Q\&A Panel and Day Two Closing

by The FDA Learning Cache

$FDA Advancing Generic Drug Development 2025: Welcome \& Keynote$

13:47

FDA Advancing Generic Drug Development 2025: Welcome \& Keynote

by The FDA Learning Cache

$FDA Advancing Generic Drugs 2025: Pharm\/Tox for the Safety Evaluation of Nitrosamine Impurities$

20:55

FDA Advancing Generic Drugs 2025: Pharm\/Tox for the Safety Evaluation of Nitrosamine Impurities

by The FDA Learning Cache

7:44:43

Generic Drugs Forum (GDF) 2025 - Day 2

by U.S. Food and Drug Administration

9:22

Comparison of SUPAC Between US (FDA) and EU (EMA)

by Pharma Learning In Depth

15:34

GDF2025 – D2S17 - Case Studies of Using Alternate Reference Standard in Bioequivalence Studies

by U.S. Food and Drug Administration

8:13

GenAI for Regulatory Affairs: Infosys in Conversation with Merck

by DIA

19:27

FDA Advancing Generic Drugs 2025: Correct Carryover for Long Half-Life Drug with Incomplete Washout

by The FDA Learning Cache

$FDA Advancing Generic Drug Development 2025: Metered Dose Inhaler \& Dry Powder Inhaler Update$

27:53

FDA Advancing Generic Drug Development 2025: Metered Dose Inhaler \& Dry Powder Inhaler Update

by The FDA Learning Cache

23:30

FDA Advancing Generic Drugs 2025: Nitrosamine Impacted Drugs Containing BCS IV Drug Substances

by The FDA Learning Cache

11:56

AGDD 2024 | D2S10-2 - Analysis of ANDA Approval and Major Deficiencies A Case Study with Topical...

by U.S. Food and Drug Administration

3:16

What's New with FDA Guidances 2025

by Vigilare Bio pharma

5:22

GDF2025 – D2S20 – Closing Remarks

by U.S. Food and Drug Administration

22:07

AGDD 2024 | D2S06 - Emerging Generic Oligonucleotides -Challenges and Progress

by U.S. Food and Drug Administration

19:46

FDA Advancing Generic Drugs 2025: Comparative Physicochemical Characterization of Iron Products

by The FDA Learning Cache

$GDF 2024 | D2S07 - Post-approval changes in Complex Generics from Drug Product\/CMC Perspectives$

25:04

GDF 2024 | D2S07 - Post-approval changes in Complex Generics from Drug Product\/CMC Perspectives

by U.S. Food and Drug Administration

Best on Vidoe

FDA Advancing Generic Drug Development 2025: Recommendations for Topical and Mucosal Products